Executive Summary
Veterinary oncology has rapidly emerged as one of the most important high-growth segments within the global companion animal healthcare industry.
Driven by:
- aging pet populations
- rising pet humanization
- increasing willingness to pursue advanced care
- major improvements in diagnostics
- expansion of specialty veterinary hospitals
- precision medicine adoption
the veterinary oncology sector is increasingly mirroring developments seen in:
- human oncology
- biologics
- targeted therapeutics
- immunotherapy
- molecular diagnostics.
Industry estimates suggest the global veterinary oncology market was valued at approximately:
- US$560–650 million in 2025 and could exceed US$1.5–2.0 billion by 2033 depending on therapeutic adoption rates and specialty care expansion.
1. Global Veterinary Oncology Market Size
Market Growth Projections
| Year | Estimated Market Size |
|---|---|
| 2024 | US$520 million |
| 2025 | US$600 million |
| 2026 | US$680–720 million |
| 2030 | US$1.1–1.3 billion |
| 2033 | US$1.5–2.0 billion |
Estimated CAGR
- 11–15%
2. Why Veterinary Oncology Is Expanding Rapidly
Major Growth Drivers
| Driver | Industry Impact |
|---|---|
| Aging pets | Higher cancer incidence |
| Better diagnostics | Earlier detection |
| Humanization of pets | Increased treatment spending |
| Pet insurance growth | Improved affordability |
| Specialty veterinary hospitals | Expanded treatment access |
| Precision medicine | Advanced oncology therapies |
| Biologics innovation | Targeted cancer treatment |
3. Cancer Incidence in Companion Animals
Dogs
Industry estimates suggest:
- nearly 1 in 4 dogs develops cancer during its lifetime
- almost 50% of dogs over age 10 may develop cancer.
Cats
Cancer incidence lower than dogs but often more aggressive.
Common feline cancers:
- lymphoma
- squamous cell carcinoma
- mammary tumors
- fibrosarcoma.
4. Most Common Veterinary Cancers
Dogs
| Cancer Type | Relative Frequency |
|---|---|
| Lymphoma | Very high |
| Mast cell tumors | Very high |
| Osteosarcoma | High |
| Hemangiosarcoma | High |
| Melanoma | Moderate |
| Mammary tumors | Moderate |
Cats
| Cancer Type | Relative Frequency |
|---|---|
| Lymphoma | Very high |
| Mammary carcinoma | High |
| SCC | Moderate |
| Injection-site sarcoma | Moderate |
5. Leading Companies in Veterinary Oncology
| Company | Core Oncology Focus |
|---|---|
| Zoetis | Pain management, biologics |
| Elanco | Specialty therapeutics |
| Virbac | Companion animal therapeutics |
| IDEXX Laboratories | Cancer diagnostics |
| PetDx | Liquid biopsy diagnostics |
| VolitionRx | Cancer blood tests |
| Torigen Pharmaceuticals | Autologous cancer vaccines |
| FidoCure | Precision oncology |
| Anivive Lifesciences | Oncology therapeutics |
6. Major Veterinary Oncology Drugs
Approved & Commercial Veterinary Oncology Drugs
| Drug | Company | Indication |
|---|---|---|
| Palladia (toceranib phosphate) | Zoetis | Mast cell tumors |
| Tanovea-CA1 | Elanco | Canine lymphoma |
| Laverdia-CA1 | Anivive | Canine lymphoma |
| Stelfonta | Virbac | Mast cell tumors |
| Oncept | Merial/BI | Canine melanoma vaccine |
7. Liquid Biopsy Revolution
Fastest-Growing Segment
Companies increasingly developing:
- blood-based cancer screening
- ctDNA testing
- molecular oncology panels
Leading Players
| Company | Technology |
|---|---|
| PetDx | Liquid biopsy |
| VolitionRx | Nu.Q cancer tests |
| FidoCure | Precision genomics |
| IDEXX | Oncology diagnostics |
Pipeline Technologies to Watch
High-Growth Areas
| Technology | Future Potential |
|---|---|
| Cancer vaccines | Very high |
| CAR-T therapy | Experimental |
| RNA therapeutics | Emerging |
| Liquid biopsy | Explosive |
| Immunotherapy | Major growth |
| AI diagnostics | Transformational |
